Clinical trial
A Double-Masked, Placebo-Controlled, Parallel Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis
NCT00404612 is registered in ClinicalTrials.gov with Lux Biosciences, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-Masked, Placebo-Controlled, Parallel Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis
- Lead sponsor
- Lux Biosciences, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 31, 2007
- Completion date
- May 31, 2009
- Enrollment
- 218 (actual)
- Sites
- 41
Conditions
As the registry lists them; a condition with its own page is linked.